Vericiguat: First Approval

Link to article at PubMed

Drugs. 2021 Mar 26. doi: 10.1007/s40265-021-01496-z. Online ahead of print.


Vericiguat (VERQUVO™; Merck & Co, Bayer AG) is a soluble guanylate cyclase (sGC) stimulator being developed for the treatment of chronic heart failure. Vericiguat stimulates sGC and cGMP production independent of nitric oxide (NO) and enhances the effects of NO by stabilizing the NO-sGC binding. Based on the results of the phase III VICTORIA trial vericiguat was recently approved in the USA for risk reduction in patients with heart failure and ejection fraction < 45%. This article summarizes the milestones in the development of vericiguat leading to this first approval.

PMID:33770393 | DOI:10.1007/s40265-021-01496-z

Leave a Reply

Your email address will not be published. Required fields are marked *